Manufacturers: BioNTech, Genentech
Autogene cevumeran is an mRNA-based cancer vaccine being jointly developed by BioNTech and Roche's Genentech. It was being evaluated as an adjuvant monotherapy in patients with high-risk stage II or stage III colorectal cancer. BioNTech ended the mid-stage trial; the trial was stopped after a review deemed it unlikely to succeed.
Autogene cevumeran is an mRNA-based cancer vaccine being jointly developed by BioNTech and Roche's Genentech. It was being evaluated as an adjuvant monotherapy in patients with high-risk stage II or stage III colorectal cancer. BioNTech ended the mid-stage trial; the trial was stopped after a review deemed it unlikely to succeed.
Adjuvant monotherapy for high-risk stage II or stage III colorectal cancer in patients whose tumors had been surgically removed but who remained ctDNA-positive.
1 associated conditions
